gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Mediator complex subunit 12

MED12, HOPA, Srb8, TRAP230, FGS1
The initiation of transcription is controlled in part by a large protein assembly known as the preinitiation complex. A component of this preinitiation complex is a 1.2 MDa protein aggregate called Mediator. This Mediator component binds with a CDK8 subcomplex which contains the protein encoded by this gene, mediator complex subunit 12 (MED12), along with MED13, CDK8 kinase, and cyclin C. The CDK8 subcomplex modulates Mediator-polymerase II interactions and thereby regulates transcription initiation and reinitation rates. The MED12 protein is essential for activating CDK8 kinase. Defects in this gene cause X-linked Opitz-Kaveggia syndrome, also known as FG syndrome, and Lujan-Fryns syndrome. [provided by RefSeq, Aug 2009] (from NCBI)
Top mentioned proteins: POLYMERASE, CAN, HAD, TRAP240, PCNA
Papers on MED12
Integrated data analysis reveals uterine leiomyoma subtypes with distinct driver pathways and biomarkers.
New
Aaltonen et al., Helsinki, Finland. In Proc Natl Acad Sci U S A, Feb 2016
In this study, we explored transcriptional differences among leiomyomas harboring different genetic drivers, including high mobility group AT-hook 2 (HMGA2) rearrangements, mediator complex subunit 12 (MED12) mutations, biallelic inactivation of fumarate hydratase (FH), and collagen, type IV, alpha 5 and collagen, type IV, alpha 6 (COL4A5-COL4A6) deletions.
RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.
Review
New
Fang, Houston, United States. In Acta Biochim Biophys Sin (shanghai), Jan 2016
Studies on clinical specimens also demonstrated that KRAS mutations are present in premalignant tissues and that most of KRAS mutant human cancers have co-mutations in other cancer driver genes, including TP53, STK11, CDKN2A, and KMT2C in lung cancer; APC, TP53, and PIK3CA in colon cancer; and TP53, CDKN2A, SMAD4, and MED12 in pancreatic cancer.
Practical issues in uterine pathology from banal to bewildering: the remarkable spectrum of smooth muscle neoplasia.
New
Oliva, Boston, United States. In Mod Pathol, Jan 2016
MED12 mutations have also a very limited role in this differential diagnosis.
Loss of imprinting of IGF2 in fibroadenomas and phyllodes tumors of the breast.
New
Noguchi et al., Suita, Japan. In Oncol Rep, Jan 2016
LOI was not associated with upregulation of IGF2 mRNA, nor were MED12 mutations and methylation status of the differentially methylated region 0 (DMR0) of IGF2.
Frequency and Spectrum of MED12 Exon 2 Mutations in Multiple Versus Solitary Uterine Leiomyomas From Russian Patients.
New
Baranov et al., Saint Petersburg, Russia. In Int J Gynecol Pathol, Jan 2016
A large proportion of UL has mutations in MED12.
Patterns of Chromosomal Abnormalities that Can Improve Diagnosis of Uterine Smooth Muscle Tumors.
New
Bullerdiek et al., Rostock, Germany. In Anticancer Res, Dec 2015
RESULTS: Two tumors, both classified as STUMP were shown to carry MED12 mutations with one of them presenting with a detectable copy number alteration.
Genomic landscapes of breast fibroepithelial tumors.
New
Impact
Teh et al., Singapore, Singapore. In Nat Genet, Nov 2015
Although MED12 mutations have been frequently found in fibroadenomas and phyllodes tumors, the landscapes of genetic alterations across the fibroepithelial tumor spectrum remain unclear.
Epidemiological and genetic clues for molecular mechanisms involved in uterine leiomyoma development and growth.
Review
New
Teixeira et al., Amsterdam, Netherlands. In Hum Reprod Update, Sep 2015
CONCLUSIONS: Menstrual cycle-related injury and repair and coinciding hormonal cycling appears to affect myometrial stem cells that, at a certain stage of fibroid development, often obtain cytogenetic aberrations and mutations of Mediator complex subunit 12 (MED12).
Endocrinology of uterine fibroids: steroid hormones, stem cells, and genetic contribution.
Review
New
Bulun et al., Chicago, United States. In Curr Opin Obstet Gynecol, Aug 2015
The recent discovery of somatic mutations involving mediator subunit complex 12 (MED12) or high-mobility group AT-hook 2 (HMGA2) in the majority of fibroids and the links to their pathophysiology were also significant advances.
MED12 and uterine smooth muscle oncogenesis: State of the art and perspectives.
Review
New
Chibon et al., Bordeaux, France. In Eur J Cancer, Aug 2015
MED12 is a subunit of the multiprotein complex Mediator, an evolutionary-conserved regulator of transcription.
Expression of CDK8 and CDK8-interacting Genes as Potential Biomarkers in Breast Cancer.
Review
Roninson et al., Columbia, United States. In Curr Cancer Drug Targets, 2014
CDK8 and its paralog CDK19, in complex with CCNC, MED12 and MED13, are transcriptional regulators that mediate several carcinogenic pathways and the chemotherapy-induced tumor-supporting paracrine network.
Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma.
Impact
Teh et al., Singapore, Singapore. In Nat Genet, 2014
Exome sequencing of eight fibroadenomas with matching whole-blood samples revealed recurrent somatic mutations solely in MED12, which encodes a Mediator complex subunit.
Integrated genomic characterization of adrenocortical carcinoma.
Impact
Bertherat et al., Paris, France. In Nat Genet, 2014
We performed exome sequencing and SNP array analysis of 45 ACCs and identified recurrent alterations in known driver genes (CTNNB1, TP53, CDKN2A, RB1 and MEN1) and in genes not previously reported in ACC (ZNRF3, DAXX, TERT and MED12), which we validated in an independent cohort of 77 ACCs.
Genome-scale CRISPR-Cas9 knockout screening in human cells.
Impact
Zhang et al., Cambridge, United States. In Science, 2014
Our highest-ranking candidates include previously validated genes NF1 and MED12, as well as novel hits NF2, CUL3, TADA2B, and TADA1.
Genetics and biomarkers in personalisation of lung cancer treatment.
Review
Impact
Karachaliou et al., Badalona, Spain. In Lancet, 2013
Overexpression of AXL and reduced MED12 function are hallmarks of resistance to tyrosine kinase inhibitors in EGFR-mutant non-small-cell lung cancer.
MED12 mutations in uterine fibroids--their relationship to cytogenetic subgroups.
GeneRIF
Bullerdiek et al., Bremen, Germany. In Int J Cancer, 2012
Leiomyomas with MED12 mutations express significantly higher levels of the gene encoding wingless-type MMTV integration site family, member 4 (WNT4) than those with HMGA2 rearrangements.
MED12 exon 2 mutations are common in uterine leiomyomas from South African patients.
GeneRIF
Aaltonen et al., Helsinki, Finland. In Oncotarget, 2011
a major role of MED12 in the genesis of leiomyomas, regardless of ethnicity
Whole exome sequencing in a random sample of North American women with leiomyomas identifies MED12 mutations in majority of uterine leiomyomas.
GeneRIF
Rajkovic et al., Pittsburgh, United States. In Plos One, 2011
An association between MED12 mutations and leiomyomas in ethnically and racially diverse American women.
MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas.
Impact
GeneRIF
Aaltonen et al., Helsinki, Finland. In Science, 2011
identified tumor-specific mutations in MED12 gene in 10 of 18 uterine leiomyomas; also found MED12 altered in 70% of tumors from 80 patients;all mutations resided in exon 2 suggesting aberrant function of this region of MED12 contributes to tumorigenesis
Mediator subunit 12 is required for neutrophil development in zebrafish.
GeneRIF
Lieschke et al., Australia. In Plos One, 2010
Mediator subunit 12 is required for neutrophil development in zebrafish.
share on facebooktweetadd +1mail to friends